Evaluation of the effect of Ivermectin in the treatment of coronavirus infectio

Phase 3

Recruiting

• Conditions: COVID-19 infection.; Coronavirus infection, unspecified; B34.2

• Registration Number: IRCT20111224008507N3
• Lead Sponsor: Mazandaran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 13 July 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Patients hospitalized with suspected Covid-19
Informed consent for inclusion in study
Age above 5 years
Weight above 15 kg

Exclusion Criteria

Liver and kidney disease
Patients with acquired immunodeficiency
Consumption of warfarin and ACEI family drugs (captopril, enalapril, etc.)
Breastfeeding

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinical symptoms including fever, chills, sore throat, cough, shortness of breath, decreased appetite, abdominal pain, dizziness, insomnia, itching, joint pain, joint swelling, headache, nausea, vomiting, diarrhea, malaise, conjunctivitis, tachycardia, wheezing, rhonchus, retraction, hypotension, rash, other symptoms. Timepoint: The first, second, third, fourth, fifth, sixth, seventh day. Method of measurement: Observation and record in checklist.;Respiratory rate and O2 saturation. Timepoint: The first, second, third, fourth, fifth, sixth, seventh day. Method of measurement: Pulse Oximeter.